| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 9, 2022 | TEVA Teva Pharmaceutical Industries Ltd | Fridriksdottir Hafrun47 | Executive VP, Global R&D | Sell | 6,116 | $9.06 | $55,412.18 | -10.6% | -16.7% | +9.2% | |
| Feb 9, 2022 | TEVA Teva Pharmaceutical Industries Ltd | Dethlefs Sven | EVP, North America Commercial | Sell | 4,138 | $9.06 | $37,491.11 | -4.5% | -16.7% | +9.2% | |
| Feb 8, 2022 | AMPH Amphastar Pharmaceuticals, Inc. | Zhou Rong59 | EVP, Production Center | Sell | 7,000 | $26.77 | $187,390.00 | -8.4% | +19.8% | +15.5% | |
| Feb 8, 2022 | AMPH Amphastar Pharmaceuticals, Inc. | Peters William J52 | CFO, EVP &Treasurer | Sell | 10,000 | $26.95 | $269,500.00 | -8.6% | +19.8% | +15.5% | |
| Feb 8, 2022 | NBIX Neurocrine Biosciences Inc | Lloyd-Smith Malcolm49 | Chief Regulatory Officer | Sell | 3,382 | $80.48 | $272,167.90 | -4.6% | -5.2% | +30.7% | |
| Feb 8, 2022 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 4,079 | $80.45 | $328,159.81 | -2.7% | -5.2% | +30.7% | |
| Feb 8, 2022 | NBIX Neurocrine Biosciences Inc | Gorman Kevin Charles55 | Chief Executive Officer | Sell | 10,984 | $80.54 | $884,674.32 | -0.6% | -5.2% | +30.7% | |
| Feb 8, 2022 | NBIX Neurocrine Biosciences Inc | Abernethy Matt57 | Chief Financial Officer | Sell | 4,290 | $80.53 | $345,485.80 | -6.9% | -5.2% | +30.7% | |
| Feb 8, 2022 | NBIX Neurocrine Biosciences Inc | Cooke Julie59 | Chief Human Resources Officer | Sell | 2,858 | $80.38 | $229,727.32 | -4.2% | -5.2% | +30.7% | |
| Feb 8, 2022 | NBIX Neurocrine Biosciences Inc | Boyer David W.51 | Chief Corp. Affairs Officer | Sell | 940 | $79.99 | $75,192.83 | -15.3% | -5.2% | +30.7% | |
| Feb 8, 2022 | NBIX Neurocrine Biosciences Inc | Roberts Eiry49 | Chief Medical Officer | Sell | 3,724 | $80.45 | $299,590.39 | -5.0% | -5.2% | +30.7% | |
| Feb 8, 2022 | NBIX Neurocrine Biosciences Inc | Benevich Eric62 | Chief Commercial Officer | Sell | 5,099 | $80.57 | $410,820.89 | -6.4% | -5.2% | +30.7% | |
| Feb 8, 2022 | NBIX Neurocrine Biosciences Inc | Gano Kyle54 | Chief Business Development Off | Sell | 6,880 | $80.61 | $554,627.74 | -1.3% | -5.2% | +30.7% | |
| Feb 7, 2022 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 24,516 | $4.41 | $108,115.56 | -6.9% | -20.4% | +81.3% | |
| Feb 7, 2022 | BUDZ Weed, Inc. | Breen Nicole M | Secretary/ Treasurer | Sell | 21,165 | $0.25 | $5,261.30 | - | - | - | |
| Feb 4, 2022 | PCRX Pacira Biosciences, Inc. | Williams Kristen Marie76 | Chief Administrative Officer | Sell | 1,000 | $65.18 | $65,180.00 | -4.3% | -0.7% | -35.0% | |
| Feb 4, 2022 | HIMS Hims & Hers Health, Inc. | Boughton Soleil | Chief Legal Officer | Sell | 49,032 | $4.50 | $220,644.00 | -6.3% | -5.6% | +77.7% | |
| Feb 3, 2022 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 6,000 | $200.10 | $1,200,615.66 | -8.5% | -6.2% | +27.2% | |
| Feb 3, 2022 | BUDZ Weed, Inc. | Breen Nicole M | Secretary/ Treasurer | Sell | 45,000 | $0.20 | $9,007.84 | - | - | - | |
| Feb 1, 2022 | AMPH Amphastar Pharmaceuticals, Inc. | Petersen Floyd F.51 | Director | Sell | 500 | $24.08 | $12,040.94 | -0.3% | +43.1% | +24.0% | |
| Jan 28, 2022 | HROW Harrow, Inc. | Opaleye Management Inc.60 | 10% Owner | Buy | 6,343 | $6.89 | $43,686.14 | +0.2% | -2.2% | +113.5% | |
| Jan 24, 2022 | INM Inmed Pharmaceuticals Inc. | Colwill Bruce | CFO | Buy | 5,000 | $1.09 | $5,438.50 | +76.7% | -30.5% | -93.4% | |
| Jan 24, 2022 | NBIX Neurocrine Biosciences Inc | Sherwin Stephen A | Director | Sell | 15,000 | $74.43 | $1,116,378.00 | -37.4% | +23.6% | +43.2% | |
| Jan 21, 2022 | PCRX Pacira Biosciences, Inc. | Williams Kristen Marie76 | Chief Administrative Officer | Sell | 200 | $65.41 | $13,082.00 | -0.9% | +20.1% | -44.0% | |
| Jan 20, 2022 | UTHR United Therapeutics Corp | Mahon Paul A47 | EVP &General Counsel | Sell | 6,000 | $205.57 | $1,233,440.17 | -5.9% | -6.4% | +30.9% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.